aluates Reports

$ 0.0

Automative

Global Hormone Sensitive Prostate Cancer Drugs Market Research Report 2024

Published Date: November 2024

Report Code: QYRE-Auto-26P18248

BUY CHAPTERS

Global Hormone Sensitive Prostate Cancer Drugs Market Research Report 2024

Code: QYRE-Auto-26P18248

Report

November 2024

Pages:85

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novartis

Merc & Co.

Bristol myers

Dendreon Corporation

GlaxoSmithKline PLC

Ferring

Roche

Celgen

Amgen Inc

TEVA

Bayer

Pfizer Inc

Hormone Sensitive Prostate Cancer Drugs Market Size

The global Hormone Sensitive Prostate Cancer Drugs market was valued at US$ 143 million in 2023 and is anticipated to reach US$ 286 million by 2030, witnessing a CAGR of 10.5% during the forecast period 2024-2030.

Hormone Sensitive Prostate Cancer Drugs Market

Hormone-sensitive prostate cancer (HSPC) drugs are a class of medications used to treat prostate cancer that is dependent on androgens, or male hormones, to grow and spread. These drugs work by reducing or blocking the production of androgens in the body, mainly testosterone, or by inhibiting androgen receptors on cancer cells. This hormonal therapy aims to slow down or stop the progression of cancer by depriving cancer cells of the hormones they need to grow. Common drugs in this category include androgen deprivation therapies (ADTs) like LHRH agonists, LHRH antagonists, and anti-androgens.

North American market for Hormone Sensitive Prostate Cancer Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Hormone Sensitive Prostate Cancer Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Hormone Sensitive Prostate Cancer Drugs in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Hormone Sensitive Prostate Cancer Drugs include Novartis, Merc & Co., Bristol-Myers, Dendreon Corporation, GlaxoSmithKline, Ferring, Roche, Celgen, Amgen, Teva, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Hormone Sensitive Prostate Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Sensitive Prostate Cancer Drugs.

The Hormone Sensitive Prostate Cancer Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hormone Sensitive Prostate Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hormone Sensitive Prostate Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hormone Sensitive Prostate Cancer Drugs Market Report

Report Metric	Details
Report Name	Hormone Sensitive Prostate Cancer Drugs Market
Accounted market size in 2023	US$ 143 million
Forecasted market size in 2030	US$ 286 million
CAGR	10.5%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Androgen Ablation Therapy Anti-androgens Chemotherapy Targeted Therapy
Segment by Application	Hospitals Clinics Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Merc & Co., Bristol-Myers, Dendreon Corporation, GlaxoSmithKline, Ferring, Roche, Celgen, Amgen, Teva, Bayer, Pfizer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hormone Sensitive Prostate Cancer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Hormone Sensitive Prostate Cancer Drugs Market growing?

Ans: The Hormone Sensitive Prostate Cancer Drugs Market witnessing a CAGR of 10.5% during the forecast period 2024-2030.

What is the Hormone Sensitive Prostate Cancer Drugs Market size in 2030?

Ans: The Hormone Sensitive Prostate Cancer Drugs Market size in 2030 will be US$ 286 million.

Who are the main players in the Hormone Sensitive Prostate Cancer Drugs Market report?

Ans: The main players in the Hormone Sensitive Prostate Cancer Drugs Market are Novartis, Merc & Co., Bristol-Myers, Dendreon Corporation, GlaxoSmithKline, Ferring, Roche, Celgen, Amgen, Teva, Bayer, Pfizer

What are the Application segmentation covered in the Hormone Sensitive Prostate Cancer Drugs Market report?

Ans: The Applications covered in the Hormone Sensitive Prostate Cancer Drugs Market report are Hospitals, Clinics, Other

What are the Type segmentation covered in the Hormone Sensitive Prostate Cancer Drugs Market report?

Ans: The Types covered in the Hormone Sensitive Prostate Cancer Drugs Market report are Androgen Ablation Therapy, Anti-androgens, Chemotherapy, Targeted Therapy

Recommended Reports

Prostate Cancer Therapeutics

Hormonal Drug Markets

Cancer Drug Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hormone Sensitive Prostate Cancer Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Androgen Ablation Therapy

1.2.3 Anti-androgens

1.2.4 Chemotherapy

1.2.5 Targeted Therapy

1.3 Market by Application

1.3.1 Global Hormone Sensitive Prostate Cancer Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Hormone Sensitive Prostate Cancer Drugs Market Perspective (2019-2030)

2.2 Global Hormone Sensitive Prostate Cancer Drugs Growth Trends by Region

2.2.1 Global Hormone Sensitive Prostate Cancer Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Hormone Sensitive Prostate Cancer Drugs Historic Market Size by Region (2019-2024)

2.2.3 Hormone Sensitive Prostate Cancer Drugs Forecasted Market Size by Region (2025-2030)

2.3 Hormone Sensitive Prostate Cancer Drugs Market Dynamics

2.3.1 Hormone Sensitive Prostate Cancer Drugs Industry Trends

2.3.2 Hormone Sensitive Prostate Cancer Drugs Market Drivers

2.3.3 Hormone Sensitive Prostate Cancer Drugs Market Challenges

2.3.4 Hormone Sensitive Prostate Cancer Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hormone Sensitive Prostate Cancer Drugs Players by Revenue

3.1.1 Global Top Hormone Sensitive Prostate Cancer Drugs Players by Revenue (2019-2024)

3.1.2 Global Hormone Sensitive Prostate Cancer Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Hormone Sensitive Prostate Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Hormone Sensitive Prostate Cancer Drugs Revenue

3.4 Global Hormone Sensitive Prostate Cancer Drugs Market Concentration Ratio

3.4.1 Global Hormone Sensitive Prostate Cancer Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hormone Sensitive Prostate Cancer Drugs Revenue in 2023

3.5 Global Key Players of Hormone Sensitive Prostate Cancer Drugs Head office and Area Served

3.6 Global Key Players of Hormone Sensitive Prostate Cancer Drugs, Product and Application

3.7 Global Key Players of Hormone Sensitive Prostate Cancer Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Hormone Sensitive Prostate Cancer Drugs Breakdown Data by Type

4.1 Global Hormone Sensitive Prostate Cancer Drugs Historic Market Size by Type (2019-2024)

4.2 Global Hormone Sensitive Prostate Cancer Drugs Forecasted Market Size by Type (2025-2030)

5 Hormone Sensitive Prostate Cancer Drugs Breakdown Data by Application

5.1 Global Hormone Sensitive Prostate Cancer Drugs Historic Market Size by Application (2019-2024)

5.2 Global Hormone Sensitive Prostate Cancer Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Hormone Sensitive Prostate Cancer Drugs Market Size (2019-2030)

6.2 North America Hormone Sensitive Prostate Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2019-2024)

6.4 North America Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Hormone Sensitive Prostate Cancer Drugs Market Size (2019-2030)

7.2 Europe Hormone Sensitive Prostate Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2019-2024)

7.4 Europe Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size (2019-2030)

8.2 Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Hormone Sensitive Prostate Cancer Drugs Market Size (2019-2030)

9.2 Latin America Hormone Sensitive Prostate Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2019-2024)

9.4 Latin America Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Size (2019-2030)

10.2 Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Hormone Sensitive Prostate Cancer Drugs Introduction

11.1.4 Novartis Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.1.5 Novartis Recent Development

11.2 Merc & Co.

11.2.1 Merc & Co. Company Details

11.2.2 Merc & Co. Business Overview

11.2.3 Merc & Co. Hormone Sensitive Prostate Cancer Drugs Introduction

11.2.4 Merc & Co. Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.2.5 Merc & Co. Recent Development

11.3 Bristol-Myers

11.3.1 Bristol-Myers Company Details

11.3.2 Bristol-Myers Business Overview

11.3.3 Bristol-Myers Hormone Sensitive Prostate Cancer Drugs Introduction

11.3.4 Bristol-Myers Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.3.5 Bristol-Myers Recent Development

11.4 Dendreon Corporation

11.4.1 Dendreon Corporation Company Details

11.4.2 Dendreon Corporation Business Overview

11.4.3 Dendreon Corporation Hormone Sensitive Prostate Cancer Drugs Introduction

11.4.4 Dendreon Corporation Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.4.5 Dendreon Corporation Recent Development

11.5 GlaxoSmithKline

11.5.1 GlaxoSmithKline Company Details

11.5.2 GlaxoSmithKline Business Overview

11.5.3 GlaxoSmithKline Hormone Sensitive Prostate Cancer Drugs Introduction

11.5.4 GlaxoSmithKline Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.5.5 GlaxoSmithKline Recent Development

11.6 Ferring

11.6.1 Ferring Company Details

11.6.2 Ferring Business Overview

11.6.3 Ferring Hormone Sensitive Prostate Cancer Drugs Introduction

11.6.4 Ferring Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.6.5 Ferring Recent Development

11.7 Roche

11.7.1 Roche Company Details

11.7.2 Roche Business Overview

11.7.3 Roche Hormone Sensitive Prostate Cancer Drugs Introduction

11.7.4 Roche Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.7.5 Roche Recent Development

11.8 Celgen

11.8.1 Celgen Company Details

11.8.2 Celgen Business Overview

11.8.3 Celgen Hormone Sensitive Prostate Cancer Drugs Introduction

11.8.4 Celgen Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.8.5 Celgen Recent Development

11.9 Amgen

11.9.1 Amgen Company Details

11.9.2 Amgen Business Overview

11.9.3 Amgen Hormone Sensitive Prostate Cancer Drugs Introduction

11.9.4 Amgen Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.9.5 Amgen Recent Development

11.10 Teva

11.10.1 Teva Company Details

11.10.2 Teva Business Overview

11.10.3 Teva Hormone Sensitive Prostate Cancer Drugs Introduction

11.10.4 Teva Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.10.5 Teva Recent Development

11.11 Bayer

11.11.1 Bayer Company Details

11.11.2 Bayer Business Overview

11.11.3 Bayer Hormone Sensitive Prostate Cancer Drugs Introduction

11.11.4 Bayer Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.11.5 Bayer Recent Development

11.12 Pfizer

11.12.1 Pfizer Company Details

11.12.2 Pfizer Business Overview

11.12.3 Pfizer Hormone Sensitive Prostate Cancer Drugs Introduction

11.12.4 Pfizer Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

11.12.5 Pfizer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novartis

Merc & Co.

Bristol myers

Dendreon Corporation

GlaxoSmithKline PLC

Ferring

Roche

Celgen

Amgen Inc

TEVA

Bayer

Pfizer Inc

List of Tables

Table 1. Global Hormone Sensitive Prostate Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Androgen Ablation Therapy

Table 3. Key Players of Anti-androgens

Table 4. Key Players of Chemotherapy

Table 5. Key Players of Targeted Therapy

Table 6. Global Hormone Sensitive Prostate Cancer Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Hormone Sensitive Prostate Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Hormone Sensitive Prostate Cancer Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Hormone Sensitive Prostate Cancer Drugs Market Share by Region (2019-2024)

Table 10. Global Hormone Sensitive Prostate Cancer Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Hormone Sensitive Prostate Cancer Drugs Market Share by Region (2025-2030)

Table 12. Hormone Sensitive Prostate Cancer Drugs Market Trends

Table 13. Hormone Sensitive Prostate Cancer Drugs Market Drivers

Table 14. Hormone Sensitive Prostate Cancer Drugs Market Challenges

Table 15. Hormone Sensitive Prostate Cancer Drugs Market Restraints

Table 16. Global Hormone Sensitive Prostate Cancer Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Hormone Sensitive Prostate Cancer Drugs Market Share by Players (2019-2024)

Table 18. Global Top Hormone Sensitive Prostate Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Sensitive Prostate Cancer Drugs as of 2023)

Table 19. Ranking of Global Top Hormone Sensitive Prostate Cancer Drugs Companies by Revenue (US$ Million) in 2023

Table 20. Global 5 Largest Players Market Share by Hormone Sensitive Prostate Cancer Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 21. Global Key Players of Hormone Sensitive Prostate Cancer Drugs, Headquarters and Area Served

Table 22. Global Key Players of Hormone Sensitive Prostate Cancer Drugs, Product and Application

Table 23. Global Key Players of Hormone Sensitive Prostate Cancer Drugs, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Hormone Sensitive Prostate Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Hormone Sensitive Prostate Cancer Drugs Revenue Market Share by Type (2019-2024)

Table 27. Global Hormone Sensitive Prostate Cancer Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Hormone Sensitive Prostate Cancer Drugs Revenue Market Share by Type (2025-2030)

Table 29. Global Hormone Sensitive Prostate Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Hormone Sensitive Prostate Cancer Drugs Revenue Market Share by Application (2019-2024)

Table 31. Global Hormone Sensitive Prostate Cancer Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Hormone Sensitive Prostate Cancer Drugs Revenue Market Share by Application (2025-2030)

Table 33. North America Hormone Sensitive Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 34. North America Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 35. North America Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 36. Europe Hormone Sensitive Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. Europe Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 38. Europe Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 39. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 40. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 41. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 42. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 44. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 47. Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 48. Novartis Company Details

Table 49. Novartis Business Overview

Table 50. Novartis Hormone Sensitive Prostate Cancer Drugs Product

Table 51. Novartis Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 52. Novartis Recent Development

Table 53. Merc & Co. Company Details

Table 54. Merc & Co. Business Overview

Table 55. Merc & Co. Hormone Sensitive Prostate Cancer Drugs Product

Table 56. Merc & Co. Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 57. Merc & Co. Recent Development

Table 58. Bristol-Myers Company Details

Table 59. Bristol-Myers Business Overview

Table 60. Bristol-Myers Hormone Sensitive Prostate Cancer Drugs Product

Table 61. Bristol-Myers Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 62. Bristol-Myers Recent Development

Table 63. Dendreon Corporation Company Details

Table 64. Dendreon Corporation Business Overview

Table 65. Dendreon Corporation Hormone Sensitive Prostate Cancer Drugs Product

Table 66. Dendreon Corporation Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 67. Dendreon Corporation Recent Development

Table 68. GlaxoSmithKline Company Details

Table 69. GlaxoSmithKline Business Overview

Table 70. GlaxoSmithKline Hormone Sensitive Prostate Cancer Drugs Product

Table 71. GlaxoSmithKline Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 72. GlaxoSmithKline Recent Development

Table 73. Ferring Company Details

Table 74. Ferring Business Overview

Table 75. Ferring Hormone Sensitive Prostate Cancer Drugs Product

Table 76. Ferring Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 77. Ferring Recent Development

Table 78. Roche Company Details

Table 79. Roche Business Overview

Table 80. Roche Hormone Sensitive Prostate Cancer Drugs Product

Table 81. Roche Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 82. Roche Recent Development

Table 83. Celgen Company Details

Table 84. Celgen Business Overview

Table 85. Celgen Hormone Sensitive Prostate Cancer Drugs Product

Table 86. Celgen Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 87. Celgen Recent Development

Table 88. Amgen Company Details

Table 89. Amgen Business Overview

Table 90. Amgen Hormone Sensitive Prostate Cancer Drugs Product

Table 91. Amgen Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 92. Amgen Recent Development

Table 93. Teva Company Details

Table 94. Teva Business Overview

Table 95. Teva Hormone Sensitive Prostate Cancer Drugs Product

Table 96. Teva Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 97. Teva Recent Development

Table 98. Bayer Company Details

Table 99. Bayer Business Overview

Table 100. Bayer Hormone Sensitive Prostate Cancer Drugs Product

Table 101. Bayer Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 102. Bayer Recent Development

Table 103. Pfizer Company Details

Table 104. Pfizer Business Overview

Table 105. Pfizer Hormone Sensitive Prostate Cancer Drugs Product

Table 106. Pfizer Revenue in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024) & (US$ Million)

Table 107. Pfizer Recent Development

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

Table 111. Authors List of This Report

List of Figures

Figure 1. Hormone Sensitive Prostate Cancer Drugs Picture

Figure 2. Global Hormone Sensitive Prostate Cancer Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Hormone Sensitive Prostate Cancer Drugs Market Share by Type: 2023 VS 2030

Figure 4. Androgen Ablation Therapy Features

Figure 5. Anti-androgens Features

Figure 6. Chemotherapy Features

Figure 7. Targeted Therapy Features

Figure 8. Global Hormone Sensitive Prostate Cancer Drugs Market Size by Application (2024-2030) & (US$ Million)

Figure 9. Global Hormone Sensitive Prostate Cancer Drugs Market Share by Application: 2023 VS 2030

Figure 10. Hospitals Case Studies

Figure 11. Clinics Case Studies

Figure 12. Other Case Studies

Figure 13. Hormone Sensitive Prostate Cancer Drugs Report Years Considered

Figure 14. Global Hormone Sensitive Prostate Cancer Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Hormone Sensitive Prostate Cancer Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Hormone Sensitive Prostate Cancer Drugs Market Share by Region: 2023 VS 2030

Figure 17. Global Hormone Sensitive Prostate Cancer Drugs Market Share by Players in 2023

Figure 18. Global Top Hormone Sensitive Prostate Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Sensitive Prostate Cancer Drugs as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Hormone Sensitive Prostate Cancer Drugs Revenue in 2023

Figure 20. North America Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Hormone Sensitive Prostate Cancer Drugs Market Share by Country (2019-2030)

Figure 22. United States Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Hormone Sensitive Prostate Cancer Drugs Market Share by Country (2019-2030)

Figure 26. Germany Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Share by Region (2019-2030)

Figure 34. China Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Hormone Sensitive Prostate Cancer Drugs Market Share by Country (2019-2030)

Figure 42. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market Share by Country (2019-2030)

Figure 46. Turkey Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. UAE Hormone Sensitive Prostate Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Novartis Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 50. Merc & Co. Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 51. Bristol-Myers Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 52. Dendreon Corporation Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 53. GlaxoSmithKline Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 54. Ferring Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 55. Roche Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 56. Celgen Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 57. Amgen Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 58. Teva Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 59. Bayer Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 60. Pfizer Revenue Growth Rate in Hormone Sensitive Prostate Cancer Drugs Business (2019-2024)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Hormone Refractory Prostate Cancer HRPCA Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Castration Resistant Prostate Cancer CRPC HRPCA Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cancer Hormone Therapy Drugs Market Insights Forecast to 2030

Global Endocrine Therapy Medication Market Research Report 2024

Global Androgen Suppression Therapy Market Insights Forecast to 2030

Endocrine Therapy Drugs ETDs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Prostate Cancer Medicine Market Insights Forecast to 2030

Global Castration Resistant Prostate Cancer Treatment Market Research Report 2024

Global Gonadotropin releasing Hormone Antagonists Market Research Report 2024

Global Steroid Hormone Drugs Market Research Report 2024

Testosterone Blocker Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Castrate resistant Prostate Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Castration resistant Prostate Cancer Drugs Market Research Report 2025

Global Benign Prostatic Hypertrophy Medication Market Research Report 2024

Global Castrate Resistant Prostate Cancer Therapeutics Market Research Report 2025

Global Antihormonal Cancer Therapies Market Insights Forecast to 2030

Global Prostate Cancer Chemotherapy Drugs Market Research Report 2025

Global LHRH for Prostate Treatment Market Research Report 2024

Global Prostate Cancer Devices Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions